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Summary 
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Background Interleukin (IL)-10 family cytokines IL-10, IL-19, IL-20, and IL-24 have 
been implicated in autoimmune diseases and we have previously reported that genetic 
variants in IL10 gene cluster were associated with psoriasis.  
Objective To analyze the relationship of genetic polymorphisms in the IL10 gene 
cluster with psoriasis. This study also explores whether there are gene–gene 
interactions among these genetic polymorphisms. 
Methods A total of 377 patients with psoriasis and 403 matched healthy controls were 
enrolled to carry out a case-control study for 48 SNPs of IL10 gene cluster. 
Genotyping for the SNPs was conducted on the Applied Biosystems 3730 DNA 
Analyzer using SNPlex™ technology. Generalized multifactor dimensionality 
reduction (GMDR) analysis was applied to discover likely gene–gene interaction 
model among the SNPs. 
Results The results showed that the alleles distributions of IL10 gene cluster SNPs are 
significantly different between case and control groups. Carriers of IL10 T allele 
(rs1554286) and of IL20 T allele (rs1400986) conferred protection to psoriasis (OR = 
0.63, Pc = 0.007; OR = 0.62, Pc = 0.038, respectively). GMDR analysis displayed a 
significant gene-gene interaction between IL10 (rs1554286) and IL20 (rs1518108) 
variants. The strongest protective effect was found with the block 1 haplotype 
ACATA  in the IL10 gene (Pc = 0.004).  
Conclusions The novel finding of the present study is gene-gene interaction of the IL-
10 pathway on the reduced risk of psoriais. Our results indicate that genetic variants 
of the immunomodulatory IL10 and IL20 genes may protective effect in the 
Europeans from Russia. Future studies are needed to confirm the results and find the 
possible functional explanation.   
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What’s already known about this topic? 
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• Psoriasis is one of the most prevalent chronic inflammatory disorders caused by 
an interplay of genetic factors and the environment on the background of 
dysregulated immune system  
• One unifying hypothesis of psoriasis pathophysiology is the cytokine network 
model. In this model either an endogenous stimulus such as HIV-1, neuropeptides, 
and medications, or an exogenous stimulus such as trauma, are represented as 
triggering a plexus of cellular events by inciting a cascade of cytokines 
What does this study add? 
• Our preliminary data suggest that two polymorphisms rs1554286 and rs1400986 
located in IL10 gene cluster related to inflammatory and immunity processes 
showed an association with protection to psoriasis.  
• Our finding suggest evidence for a two-locus interaction between the IL10 
(rs1554286) and IL20 (rs1518108) variants in the risk of psoriasis, and highlight 
further the importance of multilocus effects in the genetic component of psoriasis.  
• Haplotype analysis revealed an association of IL10 haplotype ACATA with a 
reduced risk for psoriasis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The molecular basis of the pathogenesis of psoriasis, the chronic inflammatory skin 
disease, remains unclear, but principal clinical features of psoriasis - proliferation and 
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abnormal differentiation of epidermal keratinocytes, the growth and dilation of blood 
vessels and the infiltration of leukocytes into the dermis and epidermis, appear to be 
driven mainly by various cytokines and chemokines released by the activated T-cell 
population. [1] 
Each inflammatory pathway IL-12/Th1, IL-23/Th17 and IL22/Th22 has its impact on 
psoriasis pathogenesis. Aberrant cytokine expression has been proposed as an 
underlying cause of the disease. During the past few years, the IL-10 family cytokines 
have been shown as the key cytokines involved in psoriasis – these cytokines are 
enhanced in psoriatic skin, induce many important pathological features in 
keratinocytes, and, also, IL-10 family members are essential for the development of 
psoriasis in preclinical models. IL-10 family members possess different biological 
functions, including immune suppression, elevated antiviral and antibacterial 
immunity, antitumor activity, and promotion of self-tolerance in autoimmune 
diseases, but the main functions of IL-10 family cytokine converge on protection of 
several tissues and organs from damage caused by inflammatory responses and by 
infections.  
It has been reported that expression of IL-19, IL-20, IL-22, and IL-24 cytokines 
was up-regulated in psoriasis skin.[2-6] Additionally, it was found that primary 
human keratinocytes express IL-20R1, IL-20R2 and IL-22R1.[6] IL-20 and IL-22 
promoted hyperproliferation and abnormal differentiation of keratinocytes in vitro and 
in vivo.[2,7,8] Li et al. observed that IL-19 upregulated keratinocyte growth factor 
transcripts on CD8+ T cells.[9]  IL-19, IL-20, IL-22, and IL-24 activate STAT3 either 
in keratinocyte cell lines [6] or in primary keratinocytes.[2,7,10] Some studies 
reported that IL-10 family members, but not IL-26, induce the expression of various 
antimicrobial peptides including β-defensin family genes and S100 family genes. 
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[7,10,11] These cytokines also activate proinflammatory responses through the 
induction of chemokines and cytokines from keratinocytes.[7,10]  Moreover, the IL-
10 family cytokines regulate proteins involved in tissue remodeling, including 
kallikreins KLKs, marapsin MPN, platelet-derived growth factor PDGF, and Matrix 
metalloproteinase-1, -3 MMP-1, MMP-3.[10] 
Studies with transgenic mice overexpressing IL-10 family cytokines also support 
their important pathogenic role in psoriasis. Mice overexpressing IL-20, IL-22, and 
IL-24 under the control of various promoters have been generated. [12-14] Aberrant 
cytokine expression in transgenic mice causes neonatal lethality with skin 
abnormalities, including a thickened epidermis, hyperkeratosis and compact stratum 
corneum. Stenderup et al. investigated the role of IL-20 in the aetiology of psoriasis 
by using a human skin xenograft transplantation model. These results demonstrated 
that blocking IL-20 signaling with anti-IL-20 antibodies resolved the psoriasis 
condition.[15] They also found that continuous IL-20 infusion, together with injection 
of additional nonactivated leucocytes, promotes induction of psoriasis in nonlesional 
skin from patients with psoriasis. Stenderup et al. suggested that IL-20 may play a 
critical role in the induction and maintenance of psoriasis.[15] 
Numerous of described cytokines and their receptors are involved in several 
human diseases and health conditions, including psoriasis, rheumatoid arthritis, lupus 
nephritis, and asthma.[16-19] In accordance with the proposed role of these cytokine 
in various inflammatory diseases, the polymorphisms in respective genes have also 
been associated with many immune-related conditions, especially psoriasis.[20-28] 
All these findings suggest that these cytokines may contribute to the pathogenesis of 
psoriasis. 
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In present study, we investigated the effects of 48 single nucleotide polymorphisms 
(SNPs) from IL10 gene cluster on the risk of psoriasis. In addition, a generalized 
multifactor dimensionality reduction (GMDR) analysis was performed to explore 
whether there are gene–gene interactions among the 48 SNPs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and methods 
Study subjects 
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Unrelated psoriasis patients (n=377) of European descent from the Volga-Ural region 
were studied (Table 1). All patients were hospitalized for diagnosis and treatment at 
the Republic Dermatological Hospital (Ufa, Bashkortostan). Each patient was 
evaluated according to the standard protocol including a complete history and 
physical examination. All patients had the classical pattern of skin lesions (chronic 
plaque lesions, psoriasis vulgaris), confirmed by a dermatologist. The age distribution 
of the psoriasis cases ranged from 3 to 93 years. The control cohort comprised 403 
healthy individuals. The normal control subjects were matched by sex and age with 
patients with psoriasis. Informed consent was obtained from all the healthy donors 
and patients by explaining the details of this study prior to collection of peripheral 
blood. The study was approved by the research Ethics Committee of our hospital and 
conducted according to the Declaration of Helsinki Principles.  
 
DNA extraction, marker selection and genotyping 
DNA was obtained from peripheral blood leukocytes by standard phenol extraction 
method.[29] All SNPs were genotyped at the Department of Physiology, University of 
Tartu by the ligation-based SNPlexTM genotyping system 48-plex (Applied 
Biosystems, Foster City,CA,USA) following the manufacturer’s recommended 
protocol(http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/ge
neraldocuments/cms_042019.pdf). Genotype assignments were manually confirmed 
by visual inspection with the Genemapper 4.0 (Applied Biosystems, Carlsbad, CA, 
USA) software. For the SNPs selection and SNPlex assay pool design the 
SNPbrowser v3.5 was used.[30] Using the database from Applied Biosystems, SNP 
selection was based on density of 10 kb, minor allele frequency >5% and inclusion of 
all non-synonymous SNPs.  
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Statistical analysis 
The demographic data calculations were made by SPSS 13.0 for Windows. For case-
control association studies, χ² tests with Pearson 2×2 and 2×3 contingency tables as 
implemented in PLINK version 1.06 (http://pngu.mgh.harvard.edu) were used to 
compute the P values and corresponding odds ratios (OR) with 95% confidential 
intervals for allelic association. Hardy-Weinberg equilibrium (HWE) test was 
performed using PLINK. To adjust for multiple comparisons, corrected P-value (Pc) 
for a number of comparisons (Bonferroni correction) was applied. 
Pairwise linkage disequilibrium (LD) between SNPs was quantified using the 
absolute value of Lewontin’s D’ and r² and LD plots were generated using Haploview 
version 4.1.[31,32] For determining haplotype-based associations, an accelerated 
expectation-maximization (EM) algorithm was used. To correct for multiple testing in 
comparing haplotype frequencies between the group of patients with psoriasis and the 
control group, the P values were adjusted by means of permutation testing.  
The generalised multifactor dimensionality reduction (GMDR) software 
(http://www.ssg.uab.edu/gmdr/) was applied to assess gene–gene interactions. In this 
study, we used 10-fold cross-validation and 1000-fold permutation testing. The null 
hypothesis was rejected when the P-value derived from the permutation test was 0.05 
or lower. The GMDR software provides a number of output parameters including CV 
consistency, the testing balanced accuracy, and empirical P-values to assess each 
selected interaction. The CV consistency score is a measure of the degree of 
consistency with which the selected interaction is identified as the best model among 
all possibilities considered.  
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Results 
 
Association of single markers and gene–gene interaction 
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Table 1 shows the clinical characteristics of all cases and controls. From 48 SNPs 
(Table 2), the genotyping assay for three SNPs did not work, eleven SNPs were 
monomorphic, and genotypes distribution of SNP rs1890866 deviates from HWE in 
the control population (p<0.05). Therefore, we analyzed 33 SNPs, all of which 
fulfilled the inclusion criteria of the minimum allele frequency (MAF)>0.05 for all 
samples and were in HWE in the control group. 
Allele frequencies and allelic P-value of SNPs in the psoriasis patients compared to 
the control group are presented in the Table 3. There were no significant differences 
in allele frequencies for any of the IL10 family SNPs between patients with psoriasis 
and controls. Only the T allele of rs1554286 and T allele of rs1400986 were 
significantly increased in healthy controls compared with psoriaisis patients when 
adjusted for multiple comparisions. Thus, carriers of IL10 T allele (rs1554286) and of 
IL20 T allele (1400986) conferred protection to psoriasis (OR = 0.63, Pc = 0.007; OR 
= 0.62, Pc = 0.038, respectively).  
Table 4 presents the results of cross-validation consistency (CVC) and testing 
accuracy obtained from GMDR analysis of the data. GMDR analysis revealed an 
interaction between the IL10 and IL20 polymorphisms (Pc = 0.001). The model 
including two SNPs IL20 rs1518108/IL10 rs1554286 had the testing balanced 
accuracy of 56.17%, the maximum CV consistency of 9/10, and a sign test P-value 
0.001, and the result remained statistically significant after correction (Figure1).  
 
 
Association of haplotypes 
Haplotype analysis of the IL10 gene cluster was performed according to the pairwise 
linkage disequilibrium pattern observed within each of these genes (cases and 
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controls:  N=780). The results of the haplotype specific analyses are shown in Table 
5. The haplotypes with a frequency below 1% were excluded from analyses, 
improving statistical power. The linkage disequilibrium (LD) analysis indicated the 
existence of six haplotypes blocks in the chromosome 1 region in Russians (Figure2). 
The first haplotype  block (3 kb) includes five SNPs across the IL10 gene (rs3024498, 
rs1878672, rs3024492, rs1554286, rs1518111) and the second haplotype block (4 kb) 
includes five SNPs from the IL10 gene (rs3021094, rs3024490, rs1800872, 
rs1800893, rs1800890). The third haplotype block (1 kb) includes two SNPs across 
the IL19 gene (rs2243156, rs2243158) and the fourth haplotype block (5 kb) includes 
five SNPs from the IL19 gene (rs2243168, rs2073186, rs2073185, rs2243176, 
rs2243188). The fifth haplotype block (24 kb) contains one SNP from the IL19 gene 
(rs2243191) and five SNPs across the IL20 gene (rs1713239, rs1400986, rs3024517, 
rs2981573, rs2232360). The sixth haplotype block (1 kb) contains three SNPs from 
the IL20 gene (rs2232363, rs3024523, rs1518108) and six SNPs across the IL24 gene 
(rs291111, rs1150254, 1150255, rs1150258, rs291107, rs3748669).  
Additionally, the haplotype analysis provided six haplotypes significantly associated 
with decreased and increased disease susceptibility in the psoriasis patients (Table 5). 
Namely, the block 2 haplotype AGCAA, the block 5 haplotype CGCAAA, the block 
6 haplotype ATCAAGAAC frequencies were significantly higher in patients with 
psoriasis compared to the control group (35.1% vs. 28.9%, 57.3% vs. 51.5%, 3.3% vs. 
1.6%, respectively; Table 5 and Figure 2). While the block 5 haplotype CGTGAA and 
haplotype CGTAAA frequencies were significantly higher in control group compared 
to the patients with psoriasis (10.0% vs. 14.0%, 1.7% vs. 3.4%, respectively; Table 5 
and Figure2). However, the associations did not survive multiple correction test. Only 
the block 1 haplotype ACATA in the IL10 gene displayed a statistically significant 
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association with psoriasis when adjusted for multiple comparisons (Pc =0.004) (Table 
5). This association was caused by effect of rs1554286 and rs1518111 SNPs in the 
IL10 gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
IL-19, IL-20 and IL-24 have been identified as IL-10-like cytokines, based on their 
analogous cellular sources, protein structure, receptors, target cell, genomic 
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localization and exon-intron structures. IL10 gene cluster locates in a 200 kb region 
on chromosome 1q31-32, and the three cytokine share a common receptor IL-
20R1/IL-20R2 heterodimer. [33, 34] These cytokines display many overlapping 
functions due to the similarity and shared receptor usage. Significant commonality 
exist also through conserved signaling cascades: the binding of IL-10 related cytokine 
to their receptors activates the JAK (Junus kinase), STAT (signal trasducers and 
activator of transcription), and the MAPK (mitogen-activated protein kinase) 
pathways.[35-43] Though, the IL-10 family members mediate diverse activities, 
including enhanced antibacterial and antiviral immunity, immune and antitumor 
activities, and promotion of self-tolerance in autoimmune diseases. [44-46] 
In the present study we analyzed the association of SNPs in the IL10 gene cluster 
with psoriasis. We have applied three different statistical to this data set – single SNP 
analysis, haplotype analysis and gene-gene analysis, each having different strengths 
with the aim of optimizing our ability to define the genetic architecture of psoriasis in 
the IL10 region. In the allelic tests, the strongest associations were seen with two 
SNPs in IL10 gene cluster, rs1554286 and rs1400986 (Pc = 0.007, Pc = 0.038, 
respectively). We identified a 2-locus interaction on psoriasis in GMDR analyses (Pc 
= 0.001), involving two genetic variants of IL10 and IL20. Our finding suggest 
evidence for a two-locus interaction between the IL10 (rs1554286) and IL20 
(1518108) variants in the risk of psoriasis, and highlight further the importance of 
multilocus effects in the genetic component of psoriasis.  
The importance of examining haplotype of gene clusters has clearly been 
demonstrated in several studies. [47,48,49] The haplotype analysis provided one 
haplotype significantly associated with decreased disease susceptibility. Namely, the 
block 1 haplotype ACATA in the IL10 gene frequency was significantly higher in 
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patients with psoriasis compared to the control group (Pc = 0.004). Therefore, our 
study supports a role of IL10 and the IL20 polymorphisms in the development of 
psoriasis.   
Genetic association studies and preclinical data in psoriatic models support the 
functions of IL-10 subfamily cytokines in psoriasis. Candidate SNP approaches 
suggest that IL10, IL19, IL20, and IL24 are associated with susceptibility to psoriasis 
[19-27]. These data have not been independently confirmed in genome wide 
association studies (GWAS). IL-23 plays an important role in the development of 
psoriasis. The IL-23 p40 subunit and the IL-23 receptor have been associated with 
psoriasis in genome-wide association studies. [50-53] IL-23 does not directly target 
keratinocytes. Its pathogenic functions on keratinocytes are mediated through the IL-
10 subfamily cytokines, especially IL-22.  
The positive association of the IL10.G13 allele with familial psoriasis has been 
reported, suggesting that the IL10 locus contributes to the heritability of psoriasis 
susceptibility.[19,20] Another study found that the -1082 (rs1800896) heterozygoys 
G/A genotype,[21]  -2763 (rs6693899) A allele and extended AAGC (rs1800890, 
rs6693899, rs1800896, rs1800872) haplotype [22] are associated with late-onset 
psoriasis. Kingo et al. analyzed three SNPs at the IL10 5'flanking region (−1082 
(rs1800896), −592 (rs1800872), −819C/T (rs1800871)) and identified that the IL10 
ACC haplotype is associated with lower activity of the disease, and ATA haplotype 
with persistent eruption.[23] A meta-analysis involving Asian psoriasis patients (N = 
1018) and controls (N = 1186) found significant association between psoriasis and the 
IL10-1082G allele (P = 0.011).[54]  
Associations between IL19, IL20 and IL24 polymorphisms and psoriasis have also 
been assessed. In the individual evaluation of SNPs of IL19, IL20 and IL24 genes in a 
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sample of unrelated Caucasian psoriasis patients IL19 SNP rs2243188, IL20 SNPs 
rs2981572 and rs1518108 had significant association with psoriasis.[24,25] Kõks et 
al. showed block-like structure of LD formed by the genes IL19, IL20, and IL24. They 
found extended haplotype (CACCGGAA) formed by eight SNPs in IL19 (rs2073186, 
rs2243174, rs2243188, rs2243191, rs2243193) and IL20 (rs2981572, rs2981573, 
rs2232360) genes to be a significant susceptibility factor for psoriasis, while the 
IL20/IL24 extended haplotypes (SNPs rs1518108, rs3762344, rs1150253, rs1150256, 
rs1150258) CAAAC, TGGGT, and CGAGT have been demonstrated to be protective 
against psoriasis. These data indicate that different loci within the chromosome 1q32 
possess different effects in susceptibility to psoriasis.  [25] Similar haplotype block 
structure encompassing the IL10, IL19 and IL20 genes was also established in African 
Americans and European Americans. Oleksyk et al. found that the IL10 rs6703630, 
rs6693899, and rs3024498, and IL10 haplotype AAGCG, as well as the SNPs in IL19, 
rs22443191, and IL20, rs1400986, rs3024517, rs2232360 and also two haplotypes 
CTGAAC and TCAGGC in the IL19/IL20 region had an effect on HCV clearance in 
Africans but not European-American patients with HCV infection. [55] Whereas part 
of the SNPs investigated in our study are distinct from those examined in the above 
studies, all studies suggest that carriage of IL10 and IL19/IL20 haplotypes may 
influence inflammatory response. Our study had a few limitations: firstly, we did not 
have a replication cohort in the present study, which would have validated our results, 
and secondly, the limited sample size. Further studies of different populations are 
required to examine the combined influence of these variants of the IL-10 signaling 
pathway on the pathogenesis of psoriasis. Two SNPs were associated with psoriasis in 
this study: rs1554286, which is located at the intronic boundary of intron 3, creating a 
putative location of an alternate splicing, and rs1400986 at promoter. Polymorphisms 
 17 
in the promoters are likely to deeply affect RNA amount and consequently protein 
synthesis as these regions harbour several motifs binding to transcription regulatory 
factors. 
Several authors have demonstrated the role of IL10 rs1554286 in the pathogenesis 
Benign Prostate Hyperplasia,[56] Behçet’s Disease,[57] Invasive Haemophilus 
Inﬂuenzae Serotype b Infection,[58] Leprosy,[59] and Ischemic Stroke.[60] The SNPs 
in IL10, IL10RA and IL10RB genes have been studied in Korean population, the TT 
genotype of rs1554286 were associated with small prostate volume.[56] Nobuhisa M 
et al. conducted a genome-wide association study in a Japanese cohort including 612 
individuals with Behçet’s disease and 740 unaffected individuals. Authors identified 
two suggestive associations on chromosomes 1q32.1 (IL10, rs1554286, P = 8.0-10-8) 
and 1p31.3 (IL23R-IL12RB2, rs12119179, P = 2.7-10-8).[57] In a case-control study 
performed in UK children with Hib vaccine failure, the recessive homozygous 
genotype for SNP rs1554286 in strong linkage disequilibrium with both the C-819T 
and C-592A promoter polymorphisms in the IL10 gene was associated with 
epiglottitis only (OR = 5.8; P = 1.1-10-5).[58]  Aggarwal et al. analyzed the SNP 
rs1554286 of IL10 in 807 Indian patients and found a strong association between 
rs1554286 and leprosy.[59] The rs1554286 (TT vs. CT+CC genotype, OR=1.59; 
1.06-2.39) was significantly associated with ischemic stroke even after controlling for 
age, sex, smoking, systolic blood pressure, total cholesterol, glucose, body mass index 
and serum IL-10 in a case-control study.[60]  
Genetic polymorphism rs1400986 in IL20 gene has been shown to be associated 
with Juvenile Idiopathic Arthritis, chronic hepatitis B virus and HCV clearence.[61-
64] A study performed in 219 Juvenile Idiopathic Arthritis (JIA) from UK detected 
that rs1400986 of IL20 gene conferred a risk of developing the diseases (OR = 1.53, P 
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= 0.0004).[61] Association at this SNP rs1400986 was previously identified by Fife et 
al. in  172 UK patients with JIA.[41 62] Truelove et al. analyzed rs1400986 of IL20 
gene in patients with chronic hepatitis B virus and found a strong association between 
rs1400986 and chronic hepatitis B infection outcome.[63] SNP rs1400986 was 
associated with HCV clearence in Africans Americans (91 clearence cases and 183 
chronically infected matched controls; P = 0.005 – 0.002), however, no significant 
associations were detected in European Americans (108 clearence and 245 
chronic).[64] Many associations seen at IL20, with is important in the inflammatory 
response, suggest that this gene may be significant in psoriasis.  
In conclusion, the novel finding of the present study is gene-gene interaction of the 
IL-10 pathway on the reduced risk of psoriais. Our results indicate that genetic 
variants of the immunomodulatory IL10 and IL20 genes may protective effect in the 
Europeans from Russia. In addition, this observation needs to be confirmed in other 
population to exclude the possibility of a type I error due to limited sample size.  
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Table 1  
Demographic and clinical information 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subphenotype Cases 
N=377 
Controls 
N=403 
 
Male:female ratio of affected 240:137 226:177 
Age affected at entry to the study   
Median  41 43 
Range 7-93 8-90 
Number of affected with age of onset   
<40 years (type I psoriasis) 280  
>40 years (type II psoriasis) 97  
Number of affected with family history 127  
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Table 2 
Characteristics of studied SNPs 
№ rs SNP Chr Base positions 
Major/minor 
alleles Gene Function 
1 rs10877 1 205258803 C/T C1orf116 3' UTR 
2 rs1150254 1 205139138 A/G IL24 intron 
3 rs1150255 1 205139582  G/A IL24 intron 
4 rs1150258 1 205141528 A/G IL24  exon  Tyr125His 
5 rs11589 1 204828561 A/G RASSF5  3'UTR 
6 rs13208 1 204894785 G/A DYRK3 intron 
7 rs1400986 1 205105309 C/T IL20 promoter 
8 rs1518108 1 205109797 C/T IL20 3' of a gene 
9 rs1518111 1 205011268 G/A IL10 intron 
10 rs1539243 1 204714410 C/T IKBKE exon IIe67IIe  
11 rs1554286 1 205010856 C/T IL10 intron 
12 rs1713239 1 205104098 C/G IL20 5' of a gene 
13 rs1800872 1 205013030 C/A IL10 promoter   
14 rs1800890 1 205015988 A/T IL10 promoter  
15 rs1800893 1 205013790 G/A IL10 promoter  
16 rs1878672 1 205010336 G/C IL10 intron 
17 rs188334 1 205146238 T/C FAIM3 exon  non-coding  
18 rs1890865 1 205219379 A/G FCAMR promoter  
19 rs1890866 1 205229519 G/A NA intergenic 
20 rs2073185 1 205077351 C/T IL19 intron 
21 rs2073186 1 205077249 G/A IL19 intron 
22 rs2232360 1 205107282 A/G IL20 intron 
23 rs2232361 1 205108466 G/A IL20 exon Gln155Gln 
24 rs2232362 1 205108564 G/A IL20 3' UTR 
24 rs2232363 1 205108656 A/G IL20 3' UTR 
26 rs2243156 1 205072837 G/C IL19 intron 
27 rs2243158 1 205074264 G/C IL19 5'UTR 
28 rs2243164 1 205075189 T/C IL19 intron 
29 rs2243168 1 205076011 A/T IL19 intron 
30 rs2243176 1 205079067 C/T IL19 intron 
31 rs2243188 1 205081095 C/A IL19 intron 
32 rs2243191 1 205082580 C/T IL19 missense Phe213Ser 
33 rs2275531 1 205175739 G/A PIGR missense Gly365Ser 
34 rs291102 1 205173101 C/T PIGR missense Ala580Val 
35 rs291107 1 205141794 A/G IL24 intron 
36 rs291111 1 205136149 A/G IL24 5' of a gene 
37 rs2981573 1 205107200 A/G IL20 intron  
38 rs3021094 1 205011575 A/C IL10 intron  
39 rs3024490 1 205011934 G/T IL10 intron  
40 rs3024492 1 205010735 T/A IL10 intron  
41 rs3024498 1 205008152 A/G IL10 3' UTR 
42 rs3024517 1 205106876 A/G IL20 intron  
43 rs3024523 1 205109307 T/C IL20 3' of a gene 
44 rs3093426 1 205140097 G/A IL24 intron 
45 rs3093438 1 205143833 A/T IL24 3' UTR 
46 rs3748669 1 205143646 C/G IL24 3' UTR 
47 rs9242 1 204704018 T/C SRGAP2 3' UTR 
48 rs944769 1 204758700 C/T RASSF5 intron 
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Table 3 
Association analysis of SNPs from IL10 gene cluster with psoriasis  
 
Gene SNP ID Alleles 
1/2 
MAFa(%) 
Cases 
MAF (%) 
Controls 
P-value Pc-value OR (95%CI)b 
IL10 rs1878672 G/C 41.02 37.79 0.145  1.14 (0.93-1.40) 
 rs1554286   T/C 19.64 27.72 0.00023 0.007c 0.63 (0.50-0.81) 
 rs1518111   A/G 23.60 29.90 0.005  0.72 (0.57-0.91) 
 rs3021094 C/A 9.16 11.11 0.211  0.80 (0.57-1.13) 
 rs3024490 T/G 25.76 30.41 0.044  0.79 (0.63-0.99) 
 rs3024492 T/A 23.55 22.22 0.537  1.07 (0.84-1.37) 
 rs3024498 G/A 23.55 22.72 0.699  1.04 (0.82-1.33) 
 rs1800872   A/C 25.62 30.54 0.034  0.78 (0.62-0.98) 
 rs1800893 A/G 41.37 37.60 0.133  1.17 (0.95-1.44) 
 rs1800890 A/T 35.22 28.92 0.008  1.33 (1.07-1.66) 
IL19 rs2243156 C/G 11.58 12.50 0.581  0.91 (0.67-1.24) 
 rs2243158 C/G 12.36 13.13 0.653  0.93 (0.68-1.26) 
 rs2243168 T/A 11.40 12.21 0.624  0.92 (0.67-1.26) 
 rs2073186   A/G 30.36 31.65 0.587  0.94 (0.75-1.17) 
 rs2073185 T/C 17.95 18.86 0.645  0.94 (0.72-1.22) 
 rs2243176 T/C 18.49 19.04 0.786  0.96 (0.74-1.24) 
 rs2243188 A/C 29.58 31.35 0.457  0.92 (0.73-1.14) 
 rs2243191 T/C 29.78 29.85 0.976  0.99 (0.79-1.24) 
IL20 rs1713239 C/G 17.09 16.92 0.932  1.01 (0.77-1.32) 
 rs1400986 T/C 11.64 17.55 0.0011 0.038c 0.61 (0.46-0.82) 
 rs3024517 G/A 10.30 14.02 0.027  0.70 (0.51-0.96) 
 rs2981573 G/A 28.73 29.62 0.703  0.95 (0.76-1.19) 
 rs2232360 G/A 28.03 28.83 0.732  0.96 (0.76-1.20) 
 rs2232363   A/G 3.56 1.89 0.045  1.90 (1.00-3.63) 
 rs3024523 C/T 2.86 4.43 0.105  0.63 (0.36-1.10) 
 rs1518108 T/C 45.47 40.55 0.053  1.22 (0.99-1.49) 
IL24 rs291111   G/A 1.36 1.51 0.812  0.90 (0.38-2.10) 
 rs1150254   G/A 46.23 41.88 0.089  1.19 (0.97-1.46) 
 rs1150255 A/G 45.83 41.84 0.118  1,17 (0.95-1.44) 
 rs1150258   G/A 46.27 41.98 0.093  1.19 (0.97-1.45) 
 rs291107 G/A 46.98 43.58 0.187  1.14 (0.93-1.40) 
 rs3748669 G/C 2.74 2.38 0.662  1.15 (0.60-2.17) 
 rs3093438 T/A 2.86 2.13 0.357  1.35 (0.70-2.58) 
Significant results are shown in bold face. 
 a MAF – minor allele frequency. 
b OR: odds ratio; CI: confidence interval. 
 c – statistically significant association after  Bonferroni correction 
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Table 4 
Best gene–gene interaction models identified by the generalised multifactor dimensionality reduction 
method 
 
Models Training 
balanced 
accuracy 
(%) 
Testing 
balanced 
accuracy 
(%) 
Cross-
validation 
consistency 
Sign 
test 
 
IL20 rs1518108/ IL10 rs1554286 
 
 
58.8 
 
56.1 
 
9/10 
 
0.001a 
 a - statistically significant association after 1000 permutations  
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Table 5 
Haplotype analysis of SNPs from IL10 gene cluster with psoriasis.  
 
Block Psoriasis 
(%) 
Control sample 
(%) 
χ² 
Statistic 
P-value Pc-value 
Block 1 a  IL10 (rs3024498, rs1878672, rs3024492, rs1554286, rs1518111) 
ACACG 97(35.5)  98(32.9) 1.14 0.285  
ACATA 54(19.7) 82(27.6) 13.21 0.0003 0.004b 
GGTCG 64(23.6) 66(22.2) 0.48 0.488  
AGACG 48(17.5) 44(14.6) 2.28 0.118  
ACACA 10(3.70) 7(2.30) 2.56 0.109  
Block 2  IL10 (rs3021094, rs3024490, rs1800872, rs1800893, rs1800890) 
AGCGT 90(32.8) 95(31.9) 0.12  0.724  
AGCAA 96(35.1) 86(28.9) 6.91 0.008  
ATAGT 46(16.8) 60(20.0) 2.63 0.104  
CTAGT 23(8.60) 33(11.0) 2.39 0.122  
AGCAT 17(6.3) 24(8.2) 1.99 0.158  
Block 3  IL19 (rs2243156, rs2243158) 
GG 239(87.4) 258(86.7) 0.16 0.681  
CC 32(11.6) 36(12.2) 0.16 0.686  
Block 4  IL19  (rs2243168, rs2073186, rs2073185, rs2243176, rs2243188)  
AGCCC 190(69.5) 203(68.2) 0.30 0.584  
AATTA 48(17.5) 55(18.6) 0.32  0.570  
TACCA 31(11.3) 37(12.4) 0.40 0.525  
Block 5 IL19/ IL20 (rs2243191, rs1713239, rs1400986, rs3024517, rs2981573, rs2232360) 
CGCAAA 156(57.3) 153(51.5) 5.27 0.021  
TCCAGG 47(17.1) 52(17.3) 0.01 0.898  
CGTGAA 27(10.0) 42(14.0) 5.81 0.015  
TGCAGG 31(11.3) 35(11.9) 0.10 0.749  
CGTAAA 5(1.7) 10(3.4) 4.74 0.029  
TGCAAA 5(1.8) 4(1.2) 1.09 0.296  
Block 6  IL20/ IL24 (rs2232363, rs3024523, rs1518108, rs291111, rs1150254, 1150255, rs1150258, 
rs291107, rs3748669) 
GTCAAGAAC 125(45.9) 151(50.8) 3.63 0.056  
GTTAGAGGC 117(42.9) 115(38.5) 3.10 0.078  
GCCAAGAAC 7(2.60) 11(3.80) 1.80 0.179  
ATCAAGAAC 9(3.30) 5(1.60) 4.72 0.029  
GTTAGAGGG 5(1.70) 4(1.40) 0.246 0.619  
 
Significant results are shown in bold face. 
   a - haplotype combinations with less than 1% frequency are not displayed 
   b - statistically significant association after 1000 permutations  
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